Summary
A thirty-seven year old male patient with heavily pretreated metastatic testicular carcinoma received escalating doses of recombinant human erythropoietin (EPO) before and throughout chemotherapy. Whereas previous chemotherapy regimens repeatedly caused anemic situations in this patient (hemoglobin (HB) 7.0g/dl requiring multiple transfusions of red blood cells), EPO given as an i.v. bolus injection at escalating doses of 150 to 300 U/kg body weight (BW) twice/week, starting two weeks prior to the identical myelosuppressive treatment protocol, maintained HB at levels above 8.8 g/dl and thus obviated the need for erythrocyte transfusion. EPO was discontinued after 9 weeks of administration when the patient had achieved a hematocrit (HCT) of 41.1% and a HB of 12.7 g/dl. However, erythropoiesis continued to recover for the next 7 weeks reaching a HCT of 42.4% and a HB of 14.3 g/dl, although the next identical chemotherapy cycle had been given within this period. Along with the rise in HB, ferrokinetics changed significantly as measured by serum ferritin, which was reduced to one third at the end of EPO therapy after only 9 weeks (from 979 ng/ml to 320 ng/ml). No side effects due to EPO administration occurred. These data provide first evidence for efficacy of EPO in chemotherapy-induced anemia and may open new avenues for its clinical application.
Similar content being viewed by others
References
Dessypris EN, Graber SE, Krantz SB, Stone WJ (1987) Effects of recombinant erthropoietin on human marrow hematopoietic progenitors. Blood 70: 132a
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J med 316: 73–80
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L (1988) Effects of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma for the urothelium. N Engl J Med 318: 1414–1422
Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — A phase I/II trial. Blood 73: 31–37
Goldwasser E, Kung C, Eliason J (1974) On the mechanism of erythropoietin-induced differentiation. J Biol Chem 249: 4202–4206
Herrmann F, Lindemann A, Klein H, Lübbert M, Schulz G, Mertelsmann R (1989) Effect of GM-CSF in patients with myelodysplastic syndrome with excess of blasts. Leukemia 3: 335–338
Herrmann F, Schulz G, Wieser M, Kolbe K, Noack M, Lindemann A, Mertelsmann R (1989) Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy (Submitted)
Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J (1989) Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Int Med 110: 108–114
Oster W, Herrmann F, Lindemann A, Mertelsmann R (1989) Experimental and clinical evaluation of erythropoietin. In: Habenicht (ed) Growth factors, differentiation factors, and cytokines. Springer (in press)
Oster W, Herrmann F, Brune T, Gamm H, Zeile G, Cicco A, Lindemann A, Schulz G, Mertelsmann R (1989) Effects of erythropoietin in patients with anemia due to various hematological disorders (submitted)
Schmoll HJ (1981) VP-16 Mono- und Kombinationschemotherapie beim therapierefraktären Hodenkarzinom. In: Seeber S, Nagel G (eds) Etoposid, derzeitiger Stand und neue Entwicklungen in der Chemotherapie maligner Neoplasien. Zukkerschwerdt, München, pp 178–90
Schofield R, Laitha LG (1977) Erythropoiectic effects on stem cell population. In: Fisher JW (ed) Kidney hormones. Academic Press, London, pp 283–310
Spivac JL (1986) The mechanisms of action of erythropoietin. Int J Cell Cloning 4: 139–166
Till JE, McCulloch EA (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14: 213–222
Watari K, Asano S, Shirajuji N, Kodo H, Ozawa K, Takaku F, Kamachi S (1989) Serum granulocyte colony- stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 73: 117–122
Williams S, Einhorn L (1985) Disseminated germ line tumors: A comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP-16 (BEP). Proc ASCO 4: C-390
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. The Lancet II: 1175–1178
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oster, W., Herrmann, F., Cicco, A. et al. Erythropoietin prevents chemotherapy-induced anemia: Case report. Blut 60, 88–92 (1990). https://doi.org/10.1007/BF01720513
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01720513